Revolution Medicines : Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
October 24, 2020 at 10:40 am EDT
Share
Johanna Bendell, Susanna V. Ulahannan, Marianna Koczywas, Julie Brahmer, Anna Capasso, S. Gail Eckhardt, Michael S. Gordon, Caroline Mccoach, Misako Nagasaka, Kimmie Ng, Jose Pacheco, Jonathan W. Riess, Alexander I Spira, Conor Steuer; Richa Dua, Suman Chittivelu, Serena Masciari, Zhengping Wang, Xiaolin Wang, Sai-Hong I. Ou
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 24-25, 2020; held virtually; Presentation ORAL-005
Download Presentation
Attachments
Original document
Permalink
Disclaimer
Revolution Medicines Inc. published this content on 24 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2020 14:39:04 UTC
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Revolution Medicines : Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
REVOLUTION MEDICINES, INC. 
